Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
A phase 2 trial of Regorafenib in hepatocellular carcinoma, run by Zhejiang Hisun Pharmaceutical Co. Ltd., now recruiting.
Overview
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07310173 by Zhejiang Hisun Pharmaceutical Co. Ltd., with 75 participants planned, started 2026-01-01 and due to reach its primary completion in 2027-10-01. Interventions recorded: AST-3424, Regorafenib Tablets. Conditions listed: HCC - Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRESORCE
Shares Regorafenib, Hepatocellular carcinoma.
- TargetCRAF (RAF1)
Shares Regorafenib, Hepatocellular carcinoma.
- TargetTIE2 receptor (TEK)
Shares Regorafenib, Hepatocellular carcinoma.
- PathwayHepatocellular carcinoma (KEGG map)
Shares Regorafenib, Hepatocellular carcinoma.
- PathwayThe angiogenic switch & tumour vessels
Shares Regorafenib, Hepatocellular carcinoma.